Engineered affinity proteins for tumour-targeting applications
2009 (English)In: Biotechnology and applied biochemistry, ISSN 0885-4513, E-ISSN 1470-8744, Vol. 53, 1-29 p.Article, review/survey (Refereed) Published
Targeting of tumour-associated antigens is an expanding treatment modality in clinical oncology as an alternative to, or in combination with, conventional treatments, such as chemotherapy, external-radiation therapy and surgery. Targeting of antigens that are unique or more highly expressed in tumours than in normal tissues can be used to increase the specificity and reduce the cytotoxic effect on normal tissues. Several targeting agents have been studied for clinical use, where monoclonal antibodies have been the ones most widely used. More than 20 monoclonal antibodies are approved for therapy today and the largest field is oncology. Advances in genetic engineering and in vitro selection technology has enabled the feasible high-throughput generation of monoclonal antibodies, antibody derivatives [e.g. scFvs, Fab molecules, dAbs (single-domain antibodies), diabodies and minibodies] and more recently also non-immunoglobulin scaffold proteins. Several of these affinity proteins have been investigated for both in vivo diagnostics and therapy. Affinity proteins in tumour-targeted therapy can affect tumour progression by altering signal transduction or by delivering a payload of toxin, drug or radionuclide. The ErbB receptor family has been extensively studied as biomarkers in tumour targeting, primarily for therapy using monoclonal antibodies. Two receptors in the ErbB family, EGFR (epidermal growth factor receptor) and HER2 (epidermal growth factor receptor 2), are over-expressed in various malignancies and associated with poor patient prognosis and are therefore interesting targets for solid turnours. In the present review, strategies are described for tumour targeting of solid turnours using affinity proteins to deliver radionuclides, either for molecular imaging or radiotherapy. Antibodies, antibody derivatives and non-immunoglobulin scaffold proteins are discussed with a certain focus on the affibody (Affibody (R)) molecule.
Place, publisher, year, edition, pages
2009. Vol. 53, 1-29 p.
affibody molecule (Affibody (R) molecule), affinity proteins, epidermal-growth-factor-receptor family (ErbB family), molecular, imaging, radiotherapy, tumour targeting, growth-factor-receptor, single-chain fv, ankyrin repeat protein, dependent cellular cytotoxicity, positron-emission-tomography, binding, affibody molecule, yeast surface display, human breast-cancer, complementarity-determining regions, anchored periplasmic expression
IdentifiersURN: urn:nbn:se:kth:diva-18418DOI: 10.1042/ba20080287ISI: 000265988700001OAI: oai:DiVA.org:kth-18418DiVA: diva2:336465
QC 201005252010-08-052010-08-052010-12-21Bibliographically approved